全文获取类型
收费全文 | 670篇 |
免费 | 39篇 |
国内免费 | 45篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 40篇 |
妇产科学 | 23篇 |
基础医学 | 59篇 |
口腔科学 | 14篇 |
临床医学 | 88篇 |
内科学 | 129篇 |
皮肤病学 | 13篇 |
神经病学 | 36篇 |
特种医学 | 130篇 |
外科学 | 40篇 |
综合类 | 16篇 |
预防医学 | 21篇 |
眼科学 | 6篇 |
药学 | 52篇 |
中国医学 | 1篇 |
肿瘤学 | 83篇 |
出版年
2022年 | 3篇 |
2021年 | 5篇 |
2020年 | 2篇 |
2019年 | 7篇 |
2018年 | 7篇 |
2017年 | 2篇 |
2016年 | 4篇 |
2015年 | 6篇 |
2014年 | 11篇 |
2013年 | 17篇 |
2012年 | 9篇 |
2011年 | 16篇 |
2010年 | 31篇 |
2009年 | 22篇 |
2008年 | 11篇 |
2007年 | 42篇 |
2006年 | 18篇 |
2005年 | 17篇 |
2004年 | 13篇 |
2003年 | 18篇 |
2002年 | 8篇 |
2001年 | 14篇 |
2000年 | 19篇 |
1999年 | 14篇 |
1998年 | 43篇 |
1997年 | 33篇 |
1996年 | 40篇 |
1995年 | 25篇 |
1994年 | 18篇 |
1993年 | 22篇 |
1992年 | 12篇 |
1991年 | 11篇 |
1990年 | 20篇 |
1989年 | 33篇 |
1988年 | 34篇 |
1987年 | 25篇 |
1986年 | 23篇 |
1985年 | 19篇 |
1984年 | 12篇 |
1983年 | 11篇 |
1982年 | 11篇 |
1981年 | 7篇 |
1980年 | 7篇 |
1979年 | 2篇 |
1978年 | 6篇 |
1977年 | 11篇 |
1976年 | 5篇 |
1975年 | 5篇 |
1970年 | 1篇 |
1967年 | 1篇 |
排序方式: 共有754条查询结果,搜索用时 31 毫秒
71.
C Jacquillat D Khayat P Banzet M Weil P Fumoleau M F Avril M Namer J Bonneterre P Kerbrat J J Bonerandi 《Cancer》1990,66(9):1873-1878
One hundred sixty-nine patients with histologic evidence of disseminated malignant melanoma, including patients with cerebral metastases, were entered into a Phase II study of the nitrosourea fotemustine. The treatment regimen consisted of a 100 mg/m2 1 hour IV infusion every week for 3 consecutive weeks, followed by a 4- to 5-week rest period (induction therapy). In responding or stabilized patients, maintenance therapy consisted of 100 mg/m2 every 3 weeks until the disease progressed. One hundred fifty-three patients were evaluable for response. Three complete responses and 34 partial responses were observed (according to the World Health Organization criteria), leading to an objective response rate of 24.2% (95% confidence interval: 17.4% to 31.0%). Responses were also documented on cerebral (25.0%), visceral (19.2%), or nonvisceral (31.8%) metastatic sites. The median duration of response was 22 weeks (range, 7 to 80 weeks). The objective response rate in previously untreated patients was 30.7% (19 of 62 patients). The main toxicity was hematologic with delayed and reversible leukopenia and/or thrombopenia. The objective response rate observed (especially in untreated patients), the activity on cerebral metastases, and the small amount of extra-hematologic toxicity encountered suggest that fotemustine is an effective drug in disseminated malignant melanoma. 相似文献
72.
Sickle cell anemia patients have low erythropoietin levels for their degree of anemia 总被引:3,自引:1,他引:2
We have studied serum immunoreactive erythropoietin (SIE) levels in 28 patients with sickle cell anemia (SCA) without renal insufficiency and in 17 patients with nonhemoglobinopathy anemias of comparable severity using a sensitive radioimmunoassay procedure. An exponential relationship between SIE level and degree of anemia was noted in all patients. However, in nonhemoglobinopathy anemia, a sharp rise in the SIE level occurred as hemoglobin (Hb) levels fell below about 12 g/dL, whereas in sickle cell patients the increase was not marked until hemoglobin fell to about 9 g/dL. The response was more blunted in older SCA patients than in younger ones. A linear regression model relating SIE level to Hb level, presence/absence of SCA, and age explained 63% of the variation in SIE. We conclude that the serum erythropoietin levels in SCA increased at a lower hemoglobin concentration and are of a lower magnitude than that of the other anemias. 相似文献
73.
74.
75.
JB Epstein 《Oral diseases》1997,3(Z1):S124-S128
Kaposi's sarcoma (KS) is the most common neoplastic disease in patients with disease due to human immunodeficiency virus (HIV), and oral KS (OKS) is the commonest oral neoplasia. OKS has been managed by local excision, intralesional chemotherapy regional radiotherapy, and systemic chemotherapy. Comparison between studies is difficult as the severity of oral involvement is not well defined in most studies. This paper reviews the approach to the management of OKS and also presents a proposal for the clinical staging of OKS. Clinical staging of OKS will facilitate comparisons of outcomes of treatment of OKS and improve our understanding of the natural history of the neoplasia, which has varied presentation and rates of progression. 相似文献
76.
BC SHARMA RP SINGH YK CHAWLA KL NARASIMHAN KLN RAO SK MITRA JB DILAWARI 《Journal of gastroenterology and hepatology》1997,12(8):582-584
Shunt surgery is considered to be the treatment of choice in patients with non-cirrhotic portal hypertension. There is little data on the effect of side-to-side lieno-renal (SSLR) shunt on oesophageal variceal size, splenic size and splenic pulp pressure (SPP) in patients with non-cirrhotic portal hypertension. We evaluated pre- and postoperatively endoscopic grading of varices, splenic size and SPP for predicting shunt patency in 86 patients with non-cirrhotic portal hypertension: 56 with extrahepatic portal venous obstruction (EHPVO) and 30 with non-cirrhotic portal fibrosis (NCPF). The EHPVO patients with patent shunts (n= 47) showed significant reduction in SPP (pre-operative 43.56±7.9 vs postoperative 29.96±7.7 cm of saline), splenic size (6.5±2.8 vs 4.00±2.6 cm below costal margin) and varices grades (2.96±0.5 vs 0.92±0.8). Patients with blocked shunt (n= 9) did not show significant reduction in SPP and varices grades. However, there was reduction in spleen size (8.6±3.0 vs 6.3±4.3). In the NCPF group, 28 had patent shunts and showed significant reduction in SPP (46.3±13.5 vs 33.8±7.6 cm of saline), splenic size (9.1±3.3 vs 6.8±4.6 cm below costal margin) and varices grades (2.8±0.7 vs 1.05±0.96). As only two patients with NCPF had blocked shunts, no statistical comparison between patients with patent and patients with blocked shunts could be done. In conclusion, following SSLR, there is a significant reduction in SPP and varices grades in patients with patent shunts. Endoscopic grading of varices can be used to predict shunt patency. However, spleen size is not a good criteria for predicting shunt patency. 相似文献
77.
78.
79.
P Kerbrat J F Héron J P Guastalla C Lhomme A Goupil C Toussaint A Rey M Chazard L Lenaz M George 《Bulletin du cancer》1991,78(12):1133-1137
Thirty female patients with ovarian cancer of poor prognosis were included in a chemotherapy trial using high dose IV carboplatin--800 mg/m2 every 5 weeks. The subjects had three to six cycles prior to second laparotomy. Twenty-eight patients were assessable. There was no neurological, auditory or renal toxicity. Limiting toxicity was haematological, the mean neutrophil count was less than 650 mm3 and the mean platelet count less than 30,000/mm3. No death occurred from toxicity. The clinical response rate was 67%, and the surgical response rate 53.5%, with 15% complete histological responses. Survival at 18 months is 36%. A trial concerning 36 patients treated with an association of carboplatin at the same dose combined with cyclophosphamide has just been completed and the results are being analyzed. 相似文献
80.
Marie-Françoise Avril Jean Bonneterre Michelle Delaunay Edouard Grosshans Pierre Fumoleau Lucien Israel Roland Bugat Moïse Namer Didier Cupissol Pierre Kerbrat Philippe Montcuquet Véronique Arcaute Jean-Pierre Bizzari 《Cancer chemotherapy and pharmacology》1990,27(2):81-84
Summary A total of 70 patients presenting with a disseminated malignant melanoma were entered into a multicentric study of combination chemotherapy using dacarbazine and fotemustine. In all, 63 patients were evaluable, 31.8% of whom had previously received cytotoxic chemotherapy. The protocol consisted of induction treatment with a weekly infusion of 100 mg/m2 fotemustine on days 1 and 8 and a daily infusion of 250 mg/m2 dacarbazine on days 15/18 followed by a 4- to 5-week rest period. Responding and stabilized patients were given maintenance treatment comprising fotemustine (100 mg/m2, day 1) and dacarbazine (250 mg/m2, days 2/5) every 3 weeks. The response rate was 33.3% (9 complete responses (CRs) and 12 partial responses (PRs)) and was outstanding among pretreated patients (34.9%). Responses were also documented in cerebral (28.6%), visceral (23.1%) and nonvisceral (43.3%) metastatic sites. Toxicity was mainly hematologic (22.2%, grade III/IV leukopenia; 20.3%, grade III/IV thrombocytopenia) and was acceptable. These results are encouraging in terms of the antitumor activity against nonvisceral metastases (43.3%) and the percentage of CRs obtained (23.3%), and they confirm the activity of fotemustine in cerebral metastatic sites.Other investigators involved in this trial included B. AUDHUY, CHR Louis Pasteur, Colmar; A. BERNADOU, Hôtel Dieu, Paris; J. J. BONERANDI, Hôpital Ste Marguerite; F. DANIEL, Hôpital St Joseph. Paris; P. FARGEOT, Centre Georges François Leelerc. Dijon; Pr KALIS, Hôpital Sébastopol, Reims; B. LABEILLE, Hôpital Sud, Amiens; P. LAURET, Centre Henri Becquerel, Rouen; P. LTTOUX, Hôtel Dieu, Nantes; G. LORETTE, Hôpital Trousseau, Chambray les Tours: R. METZ, Centre Alexis Vautrin, Vandoeuvre les Nancy; M. MOUSSEAU, CHR de la Tronche, Grenoble; J. L. VERRET, CHR, Angers, France 相似文献